Cresset Asset Management LLC Reduces Holdings in Artivion, Inc. (NYSE:AORT)

Cresset Asset Management LLC lessened its stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 52.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,130 shares of the company's stock after selling 19,929 shares during the period. Cresset Asset Management LLC's holdings in Artivion were worth $518,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of AORT. Barclays PLC boosted its stake in shares of Artivion by 346.3% in the third quarter. Barclays PLC now owns 70,877 shares of the company's stock valued at $1,888,000 after purchasing an additional 54,996 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Artivion by 394.9% in the third quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company's stock valued at $2,606,000 after acquiring an additional 78,120 shares during the period. Calamos Advisors LLC boosted its holdings in shares of Artivion by 113.7% in the fourth quarter. Calamos Advisors LLC now owns 63,029 shares of the company's stock valued at $1,802,000 after acquiring an additional 33,541 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Artivion by 14.4% during the third quarter. Franklin Resources Inc. now owns 21,107 shares of the company's stock worth $553,000 after purchasing an additional 2,663 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new position in Artivion in the fourth quarter worth $194,000. Hedge funds and other institutional investors own 86.37% of the company's stock.

Insiders Place Their Bets

In related news, SVP Marshall S. Stanton sold 10,548 shares of the firm's stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $29.13, for a total value of $307,263.24. Following the sale, the senior vice president now directly owns 105,332 shares of the company's stock, valued at approximately $3,068,321.16. This trade represents a 9.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO James P. Mackin sold 42,156 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the completion of the transaction, the chief executive officer now owns 663,882 shares in the company, valued at $18,130,617.42. The trade was a 5.97% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 101,347 shares of company stock valued at $2,663,486 in the last ninety days. Insiders own 7.60% of the company's stock.

Artivion Trading Up 1.7%

Shares of Artivion stock traded up $0.49 during mid-day trading on Friday, hitting $29.46. 449,645 shares of the stock were exchanged, compared to its average volume of 322,190. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $32.33. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -1,473.00 and a beta of 1.54. The company has a 50-day simple moving average of $24.64 and a 200 day simple moving average of $27.30. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.06). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The firm had revenue of $98.98 million for the quarter, compared to analyst estimates of $94.81 million. Research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Wall Street Analyst Weigh In

AORT has been the subject of a number of research analyst reports. Citizens Jmp upgraded Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. Needham & Company LLC restated a "buy" rating and issued a $32.00 price target on shares of Artivion in a research report on Tuesday, May 6th. JMP Securities restated a "market outperform" rating and issued a $33.00 price target on shares of Artivion in a research report on Tuesday, May 6th. Finally, Stifel Nicolaus dropped their price target on Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Artivion has an average rating of "Buy" and a consensus target price of $31.40.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.